Business Wire

ALIPAY+

13.1.2023 10:33:43 CET | Business Wire | Press release

Share
Alipay+ Collaborates With Macao SAR Government to Boost Local Consumption and Attract Inbound Tourists

Alipay+, a provider of global cross-border digital payment and marketing solutions announced today that, through Alipay+, Macao merchants are offering lucrative incentives inside AlipayHK – one of the most popular e-wallets in Hong Kong – to attract travelers and boost local consumption as inter-city travels are expected to soon recovered to pre-pandemic levels.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230113005107/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

From January 20, users of AlipayHK will be able to find featured Macao shops and their special offers for tourists such as digital coupons inside the app’s Alipay+ Rewards section. (Photo: Business Wire)

From January 20, users of AlipayHK will be able to find featured Macao shops and their special offers for tourists such as digital coupons inside the app’s Alipay+ Rewards section – a joint effort of several parties including Macao’s Economic and Technological Development Bureau, five local chambers of commerce, Macau Pass, Ant Group and over a hundred small and medium-sized merchants in Macao.

The latest campaign inside AlipayHK’s Alipay+ Rewards section was established to boost local consumption as more and more tourists return to the city. AlipayHK, which owns most active users in Hong Kong, has been accepted at nearly 90% merchants in Macao.

“Powered by Alipay+, this online campaign on AlipayHK, which has 3.3 million active users, will help promote local Macao merchants and increase their exposures, as well as position Macao as an attractive tourist destination for travelers from Hong Kong in the short- to longer-term,” said Ng Wah Wai, Director of the Industry and Commerce Association of Macau. He added that the campaign is also expected to connect Macao merchants with more tourists from other overseas markets through Alipay+ in the future.

“With the joint efforts from all parties, we hope this campaign on AlipayHK could further explore the potential of Macao’s featured merchants via online promotion, enhance the attractiveness of Macao’s tourism consumption, encourage the second and third-time visits of tourists to Macao, and jointly create new momentum for Macao’s overall economic growth,” said Ng.

On January 8, China announced first steps to optimize regulations on travel between the mainland and Hong Kong, lifting quarantine requirements that were in place for almost three years. A surge in number of travelers between the two cities is expected in response to the relaxation of travel restrictions.

Venetia Lee, General Manager of Ant Group Greater China International Business, said: “We are pleased to work with the Macao government and five local chambers of commerce to attract more Hong Kong tourists to Macao and stimulate local tourism consumption, in recognition of AlipayHK as a valuable partner.”

“AlipayHK is dedicated to playing a greater role in the realization of connectivity in the Great Bay Area through Alipay+ payment and marketing solutions, and we will continue to work with different ecological partners in the future to provide more convenient and valuable services to our users,” she added.

Alipay+’s Expanding Global Footprint

Developed by Ant Group, Alipay+ offers unified global mobile payment and marketing solutions that connect merchants with multiple e-wallets and payment methods. Consumers can conveniently use their preferred local payment methods while transacting seamlessly in a different market and be able to enjoy marketing offers by merchants through Alipay+.

Alipay+ Rewards is a new digital marketing platform developed by Alipay+ and partner e-wallets to help global brands better engage with consumers worldwide by offering incentives and exclusive services.

Currently, Alipay+ has over 15 mobile payment partners globally, including AlipayHK, that have covered more than 1 billion digital-savvy consumers. South Korea’s Kakao Pay, another e-wallet partners of Alipay+, has also been accepted at local merchants in Macao.

Globally, over the past year, Alipay+’s merchant coverage has more than doubled since last year to over 2.5 million, which includes regional and global digital entertainment providers, lifestyle services, e-commerce platforms and a wide range of brick-and-mortar businesses that cover major airports, shopping centers, duty free shops, convenience stores, cafes, restaurants and tourism facilities.

Businesses across Japan, South Korea, Singapore, Malaysia and other Southeast Asian markets are embracing Alipay+ to connect with global digital payment methods through one-time integration, and better engage with over 1 billion consumers.

Alipay+’s merchant coverage includes over 1,000 online platforms, more than 10 major airports, over 90,000 convenience stores, over 360,000 restaurants, nearly 200,000 taxis and major hotel brands, department stores, duty-free shops and tourist facilities in Asia and Europe.

About Alipay+

Alipay+ offers unified global mobile payment and marketing solutions that connect merchants with multiple e-wallets and payment methods from different countries and regions by collaborating with global partners. Consumers can conveniently use their preferred local payment methods while transacting seamlessly in a different market and be able to enjoy marketing offers by the merchants through Alipay+. Alipay+ is developed by Ant Group, the owner and operator of Alipay, one of the world’s leading digital open platforms.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230113005107/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye